VitriVax

About VitriVax

VitriVax, a biotechnology firm established in 2014, is focused on resolving critical challenges in vaccine distribution and administration through its formulation technology. The company originated from a collaborative effort at the University of Colorado, Boulder, between Dr. Robert Garcea and Dr. Theodore Randolph, who combined their distinct expertise to create the company's core technology. Dr. Garcea brings an extensive background in medicine, virology, and pediatrics from institutions like Harvard and Stanford, with his research focusing on the structure of small DNA viruses. Complementing this is Dr. Randolph, a professor in Chemical and Biological Engineering with deep knowledge in protein stabilization and pharmaceutical biotechnology.

The company's central offering is the Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform. This technology addresses two major logistical hurdles in global health: the need for a constant cold chain and multi-dose injection schedules. The ALTA® platform makes vaccines thermostable, capable of withstanding temperatures up to 70°C (158°F) for extended periods, which eliminates the necessity for refrigeration. This is achieved by using a spray-drying process that encases vaccine antigens in a protective sugar-glass matrix. Furthermore, the platform enables single-shot administration of multi-dose vaccines. It employs atomic layer deposition (ALD) to apply nanometer-thick coatings to the vaccine particles, which allows for a timed release of subsequent doses up to six months after the initial injection.

VitriVax operates on a business-to-business model, partnering with pharmaceutical companies and vaccine developers in both human and animal health sectors. Its revenue is generated through licensing agreements for the ALTA® platform, which include upfront payments, milestone fees, and per-dose royalties. The company also provides services such as consulting and training. VitriVax has secured significant funding through multiple rounds, including grants from the Bill & Melinda Gates Foundation, the Coalition for Epidemic Preparedness Innovations (CEPI), and the U.S. Department of Defense, in addition to a Series A financing round led by Adjuvant Capital. These funds support the advancement of various vaccine projects, including those for polio, rabies, and other infectious diseases.